The paradox
===========

Hospitals around the world are striving to reduce their rates of ventilator-associated pneumonia (VAP) in order to improve patient outcomes and minimize costs. Professional societies, legislators, quality improvement advocates, and medical product manufacturers are promoting an increasing array of interventions to reduce VAP rates. These include regular oral care, elevation of the head of the bed, continuous aspiration of subglottic secretions, silver-coated endotracheal tubes, and many other initiatives. Some jurisdictions now mandate hospitals to report adherence with a subset of these \'process measures\'. Review of the literature supporting these interventions, however, reveals a striking paradox: each of these strategies dramatically reduces VAP rates but almost none has any impact on patients\' duration of mechanical ventilation, hospital length of stay, or mortality (Table [1](#T1){ref-type="table"}).

###### 

Randomized controlled trials of interventions to prevent ventilator-associated pneumonia

                                                                                Impact on                                
  ----------------------------------------------------------------------------- ----------- ----------- ---- ---- ------ -------
  Elevation of the head of the bed                                                                                       
   Drakulovic, *et al*., 1999 \[[@B5]\]                                         86          78% ↓       NS   NS   \-     NS
   van Nieuwenhoven, *et al*., 2006 \[[@B46]\]                                  221         NS          NS   NS   \-     NS
  Oral care                                                                                                              
   Chlorhexidine                                                                                                         
    DeRiso, *et al*., 1996 \[[@B40]\]                                           353         NS          NS   \-   NS     80% ↓
    Fourrier, *et al*., 2000 \[[@B1]\]                                          60          66% ↓       NS   NS   \-     NS
    Genuit, *et al*., 2001 \[[@B2]\]                                            95          37% ↓       NS   NS   NS     \-
    Houston, *et al*., 2002 \[[@B47]\]                                          561         NS          NS   \-   \-     \-
    Fourrier, *et al*., 2005 \[[@B48]\]                                         228         NS          NS   NS   \-     NS
    Koeman, *et al*., 2006 \[[@B3]\]                                            257         NS          NS   NS   NS     NS
    Segers, *et al*., 2006 \[[@B49]\]                                           954         50% ↓       \-   NS   8% ↓   NS
    Tantipong, *et al*., 2008 \[[@B50]\]                                        207         NS          \-   \-   \-     NS
    Chan, *et al*., 2007 \[[@B4]\] (meta-analysis)                              2,144       44% ↓       NS   NS   \-     NS
   Oral topical antibiotics                                                                                              
    Laggner, *et al*., 1994 \[[@B51]\] (gentamicin)                             67          NS          NS   \-   \-     NS
    Bergmans, *et al*., 2001 \[[@B52]\] (gentamicin, colistin, vancomycin)      226         57%-68% ↓   NS   NS   NS     NS
    Kollef, *et al*., 2006 \[[@B53]\] (iseganan)                                709         NS          \-   \-   \-     NS
    Chan, *et al*., 2007 \[[@B4]\] (meta-analysis)                              1,098       NS          NS   NS   \-     NS
    de Smet, *et al*., 2009 \[[@B31]\] (tobramycin, colistin, amphotericin B)   3,894       \-          NS   NS   NS     14% ↓
  Deep vein thrombosis prophylaxis                                                                                       
   Samama, *et al*., 1999 \[[@B54]\]                                            1,102       \-          \-   \-   \-     NS
   Fraisse, *et al*., 2000 \[[@B55]\]                                           223         \-          \-   \-   \-     NS
   Leizorovicz, *et al*., 2004 \[[@B56]\]                                       3,706       \-          \-   \-   \-     NS
   Mahé, *et al*., 2005 \[[@B57]\]                                              2,474       \-          \-   \-   \-     NS
  Stress ulcer prophylaxis                                                                                               
   Prod\'hom, *et al*., 1994 \[[@B58]\]                                         248         NS          \-   \-   \-     NS
   Bonten, *et al*., 1995 \[[@B59]\]                                            141         NS          \-   \-   NS     NS
   Yildizdas, *et al*., 2002 \[[@B60]\]                                         160         NS          \-   \-   \-     NS
   Kantorova, *et al*., 2004 \[[@B61]\]                                         287         NS          NS   NS   \-     NS
   Cook, *et al*., 1996 \[[@B10]\] (meta-analysis)                              7,218       NS          \-   \-   \-     NS
  Continuous aspiration of subglottic secretions                                                                         
   Valles, *et al*., 1995 \[[@B6]\]                                             153         37% ↓       \-   NS   \-     NS
   Kollef, *et al*., 1999 \[[@B62]\]                                            343         39% ↓       NS   NS   NS     NS
   Smulders, *et al*., 2002 \[[@B63]\]                                          150         75% ↓       NS   NS   NS     NS
   Lorente, *et al*., 2007 \[[@B64]\]                                           280         64% ↓       NS   NS   \-     NS
   Bouza, *et al*., 2008 \[[@B39]\]                                             690         NS          NS   NS   NS     NS
  Silver-coated endotracheal tubes                                                                                       
   Kollef, *et al*., 2008 \[[@B8]\]                                             2,003       36% ↓       NS   NS   NS     NS

ICU, intensive care unit; LOS, length of stay; NS, not statistically significant; VAP, ventilator-associated pneumonia; Ventilator LOS, duration of mechanical ventilation.

Regular oral care with chlorhexidine, for example, reduces VAP rates by up to 37% to 66% but has no impact on duration of mechanical ventilation, intensive care unit (ICU) or hospital length of stay, or mortality \[[@B1]-[@B4]\]. Likewise, elevation of the head reduces the VAP rate by 78% \[[@B5]\], continuous aspiration of subglottic secretions reduces VAP rates by 50% to 55% \[[@B6],[@B7]\], and silver-coated endotracheal tubes decrease VAP rates by 36% \[[@B8]\]. None of these investigations, though, showed an impact on patients\' outcomes. Many of these studies were not primarily powered to detect a difference in length of stay or mortality, but it is striking that they did not even show trends toward improvements in these outcomes regardless of whether considered alone or in meta-analyses that included thousands of patients \[[@B4],[@B9],[@B10]\]. The failure of these studies to detect an impact on patient outcomes is conspicuous since the balance of research does show that VAP doubles the risk of dying and increases intensive care length of stay by a mean of 6 days \[[@B11]\].

The explanation
===============

The source of this paradox lies in the ambiguity and inaccuracy inherent in VAP diagnosis. VAP is typically defined as the presence of fever, abnormal white blood cell count, purulent sputum, and new radiographic infiltrates. On intensive investigation, however, only a fraction of patients with these signs truly have histological pneumonia \[[@B12]\]. Instead, up to two thirds of people who fulfill this definition have one or more alternative conditions that range from relatively benign, such as atelectasis and tracheobronchitis, to severe, such as acute respiratory distress syndrome or pulmonary infarction \[[@B13],[@B14]\].

The addition of microbiological criteria does little to improve accuracy. Many studies define VAP as the presence of greater than 1,000 colony-forming units per milliliter on culture of bronchoalveolar lavage fluid. This definition is attractive because it is objective, but unfortunately it is no more accurate than clinical criteria alone \[[@B15]\]. The sensitivity and specificity of this definition relative to a histological gold standard are only 50%-70% and 40%-95%, respectively \[[@B16]-[@B19]\]. False positives are due to contamination of the lavage specimen by bacteria colonizing the patient\'s endotracheal tube and upper airway. This effect is particularly marked in patients with prolonged ventilation. False negatives arise from the failure to sample the correct lung segment, insufficient bacterial growth to cross the quantitative threshold, and damping of bacterial growth by prior antibiotic exposure.

Much of VAP misdiagnosis stems from bacterial colonization superimposed upon non-infectious pulmonary processes such as fluid shifts, barotrauma, atelectasis, inflammatory reactions, and exacerbations of patients\' underlying lung disease. These factors wax and wane in ways that are difficult to discern at the bedside, leading to the transient appearance of clinical syndromes suggestive of VAP. As often as not, these processes spontaneously resolve in short order without definitive therapy. Clinical trials for early empiric treatment of suspected VAP followed by reassessment 48 to 72 hours later hint at this process. In many patients, the VAP syndrome is no longer present on reassessment and antibiotics can safely be stopped without discernible impact on patient outcomes \[[@B20]-[@B22]\].

Mislabelling benign events as VAP creates bias if prevention measures preferentially affect the more benign disorders over the more serious disorders present within the spectrum of conditions that look like VAP. This is particularly likely in studies that use a microbiological definition of VAP to assess interventions that work by decreasing bacterial colonization of the endotracheal tube. For example, the NASCENT (North American Silver-Coated Endotracheal Tube) study of silver-coated endotracheal tubes compared with conventional endotracheal tubes found a statistically significant 36% reduction in microbiologically confirmed VAP yet no difference in the rate of physician-suspected VAP (26% versus 31%, *P*= 0.39) or patients with radiographic infiltrates and suggestive clinical signs (53% versus 56%, *P*= 0.74) \[[@B8]\]. This discrepancy between rates of microbiologically defined VAP versus clinically defined VAP suggests that silver-coated tubes preferentially decrease colonization rather than infection. This is further borne out by identical durations of mechanical ventilation, ICU stay, hospital stay, and mortality between patients with silver-coated versus conventional tubes. Other interventions that decrease microbial colonization, such as oral chlorhexidine and continuous aspiration of subglottic secretions, might also be subject to this bias.

Mislabelling benign events as VAP further contributes to the paradox by obscuring faint but true signals from bona fide pneumonias. Some interventions designed to prevent VAP may well reduce the frequency of bona fide pneumonias (and truly improve outcomes for this subset of patients), but the plethora of alternative conditions captured by the VAP definition dilute the signal coming from the subset of patients with true pneumonias. Generally low event rates in both the intervention and control groups of many studies compound the challenge of detecting significant impacts on outcomes. These effects may also explain some of the conflicting results in studies evaluating the attributable mortality of VAP: the failure of some studies to detect an impact on mortality \[[@B23]-[@B26]\] despite a statistically significant impact in other studies \[[@B27]-[@B29]\] and on meta-analysis \[[@B11]\] may be due to damping of the \'true\' VAP morbidity signal by misclassifying relatively benign conditions as VAP. Alternatively, VAP may be more of a marker for severity of illness in intubated patients rather than an independent source of morbidity in and of itself. Either way, the failure of multiple clinical trials to detect an impact of VAP prevention measures on patient outcomes suggests that the net benefit of these interventions on the population level is small.

The implication
===============

The near impossibility of accurate VAP diagnosis compels us to exert great caution when interpreting trial data and hospital surveillance data showing decreases in VAP rates. Lower rates in the intervention arm of clinical trials may reflect disproportionate decreases in benign mimickers of VAP rather than VAP itself. Similarly, observational reports of markedly reduced VAP rates in some hospitals may reflect measurement artefact more than true reductions in serious disease \[[@B14]\]. Before advocating their adoption, we need to see that new interventions and quality improvement programs impact meaningful outcomes rather than just VAP rates.

Likewise, legislators considering mandatory reporting of VAP prevention process measures should consider their impact on outcomes before compelling implementation. Due to the inaccuracy and ambiguity in surveillance definitions, many jurisdictions have shied away from requiring VAP reporting \[[@B14],[@B30]\]. It will be a great irony if these jurisdictions now compel hospitals to report VAP prevention process measures validated by studies that used the same imperfect VAP definitions to prove their value yet failed to show any impact on patient outcomes.

Clinicians and patients can take heart that some interventions have been shown to improve hard outcomes and do merit adoption. Selective oropharyngeal decontamination reduces ICU patients\' mortality \[[@B31]\]. Likewise, daily sedative interruptions and daily assessments of readiness to extubate consistently reduce patients\' duration of mechanical ventilation and possibly lower mortality (Table [2](#T2){ref-type="table"}) \[[@B32]-[@B38]\]. Other VAP prevention measures may decrease antibiotic usage \[[@B39],[@B40]\] but this outcome has not yet been widely studied.

###### 

Randomized controlled trials of ventilator weaning strategies

  ----------------------------------------------------------------------------------------------------------------------------------------
                                                                Impact on                                                  
  ------------------------------------------------------------- ----------- ---- ------------- ------------- ------------- ---------------
  Daily spontaneous breathing trial                                                                                        

   Esteban, *et al*., 1995 \[[@B35]\]                           546         \-   40% ↓\        \-            \-            \-
                                                                                 (-2 days)                                 

   Ely, *et al*., 1996 \[[@B34]\]                               300         \-   25% ↓\        NS            NS            NS
                                                                                 (-1.5 days)                               

   Kollef, *et al*., 1997 \[[@B33]\]                            357         \-   20% ↓\        \-            NS            NS
                                                                                 (-0.4 days)                               

   Marelich, *et al*., 2000 \[[@B32]\]                          385         NS   45% ↓\        \-            \-            NS
                                                                                 (-2.3 days)                               

   Lellouche, *et al*., 2006 \[[@B36]\]                         144         NS   38% ↓\        22.6% ↓\      NS            NS
                                                                                 (-4.5 days)   (-3.5 days)                 

  Daily sedative interruption                                                                                              

   Kress, *et al*., 2000 \[[@B37]\] and                         128         NS   33% ↓\        35% ↓\        NS            NS
                                                                                 (-2.4 days)   (-3.5 days)                 

   Schweickert, *et al*., 2004 \[[@B65]\]                                                                                  

  Daily spontaneous breathing trial and sedative interruption                                                              

   Girard, *et al*., 2008 \[[@B38]\]                            336         \-   19% ↓\        29% ↓\        22% ↓\        28 days: NS\
                                                                                 (-3.1 days)   (-3.8 days)   (-4.3 days)   1 year: 32% ↓
  ----------------------------------------------------------------------------------------------------------------------------------------

ICU, intensive care unit; LOS, length of stay; NS, no statistically significant impact; VAP, ventilator-associated pneumonia; Ventilator LOS, duration of mechanical ventilation.

There is also tentative evidence that combining interventions into bundles may impact patient outcomes even when the component interventions alone do not. Ventilator bundles typically include elevating the head of the bed, stress ulcer prophylaxis, thromboembolism prophylaxis, and a daily weaning assessment. None of these measures in isolation has been shown to decrease patients\' length of stay, yet three centers implementing these measures as a bundle reported shorter ICU lengths of stay \[[@B41]-[@B43]\] and a fourth center found shorter hospital length of stay \[[@B44]\] compared with historical rates. These studies, while promising, need to be interpreted with great caution since they suffer many methodological limitations, including the use of historical rather than concurrent controls \[[@B45]\].

For too long, we have accepted VAP as a surrogate marker for the outcomes we really care about, namely patients\' duration of mechanical ventilation, hospital length of stay, and mortality. The disparity between prevention measures\' impact on VAP rates and their lack of impact on patient outcomes underscores the inadequacy of VAP as a surrogate marker. We need to directly assess the impact of VAP prevention measures on patient outcomes before advocating or compelling their adoption.
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